BreatheMax Nasal Spray (sodium pyruvate nasal spray) / EmphyCorp, Cellular Sciences - LARVOL DELTA

The Effect of N115 on Coughing in IPF Patients (clinicaltrials.gov) - P3 | N=50 | Completed | Sponsor: Cellular Sciences, inc. | Recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ May 2024 | Trial primary completion date: Aug 2024 ➔ May 2024

Trial completion • Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

The Effect of N115 on Coughing in IDF Patients (clinicaltrials.gov) - P3 | N=50 | Recruiting | Sponsor: Cellular Sciences, inc.

New P3 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Sodium Pyruvate Nasal Spray Reduces the Severity of Nasal Inflammation and Congestion in Patients with Allergic Rhinitis. (PubMed, J Aerosol Med Pulm Drug Deliv) - " The intranasal administration of sodium pyruvate significantly improved nasal inflammation scores in all five clinical trials of patients with AR (p < 0.0001 in all trials). These results give credence to the overall ability of sodium pyruvate, administered by nasal spray, to treat inflammation of the nasal airways."

Journal • Allergic Rhinitis • Immunology • Inflammation • Respiratory Diseases • CCL2 • CXCL8 • IL6

Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers. (clinicaltrials.gov) - P2/3 | N=22 | Completed | Sponsor: Cellular Sciences, inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis (PRNewswire) - P3, N=60; NCT04824365; Sponsor: Cellular Sciences, inc.; "In a Phase III Clinical Trial with patients with Pulmonary Fibrosis, there was a statistically and clinically significant improvement in all lung functions, compared to baseline, including an increase in FEV-1, SaO2, FVC, FEV-1/FVC ratios (from 52% to 86%) and a reduction in coughing and fatigue."

P3 data • Idiopathic Pulmonary Fibrosis • Novel Coronavirus Disease • Respiratory Diseases

Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers. (clinicaltrials.gov) - P2/3; N=22; Active, not recruiting; Sponsor: Cellular Sciences, inc.; Recruiting ➔ Active, not recruiting; N=50 ➔ 22

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers. (clinicaltrials.gov) - P2/3; N=50; Recruiting; Sponsor: Cellular Sciences, inc.

New P2/3 trial • Infectious Disease • Novel Coronavirus Disease